Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR

Measles Clinical Trial

— BREMEAVAC  

Official title:

Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02325310
• Other study ID #: 2014-001538-28
• Status: Completed
• Phase: Phase 4
• Start date: February 4, 2015
• Est. completion date: November 1, 2017

Study information

• Verified date: April 2018
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In order to assess the safety of breastfed infants after their mother's postpartum immunization with a combined measles-mumps-rubella (MMR) vaccine, the purpose of this study is to investigate whether measles vaccine strain is excreted in breast milk of breastfeeding women with negative rubella and measles serologies.

Description:

This is a multicentre prospective study, to evaluate the safety of infant from 50 breastfeeding women, analyzable for primary endpoint, after postpartum immunization with MMR vaccine.

During the screening period, eligibility will be determined based on the inclusion and exclusion criteria. Medical records of pregnant women will be screened by study investigators, who will then propose to the woman to participate to the study during a phone call or a follow-up visit. Screening visit could take place 4 months before delivery planned date up until the day of delivery.

The investigator will explain the study to the woman. A copy of the informed consent documents will be given to the woman for reading and for further information about the study (by email, by post, or personally).

If the woman is willing to participate to the study and after she had given her screening informed consent, a blood sample for measles serological analysis will be drawn.

After signing the consent, women meeting all the inclusion criteria and none of the exclusion criteria will be vaccinated in post partum and before the exit of the maternity at day 0.

Each woman will have a blood draw at day 0 and breast milk samples as well as urine samples at the hospital at day 0 before vaccination.

Each included woman will also provide breast milk and urine home samples at days 7, 11 and 14 after vaccination. Reminder calls will be performed at days 7, 11 and 14 after vaccination.

Women will then be followed and vaccinated 8 weeks after the first vaccination, visit V1.

Each infant will be followed during 8 weeks. An optional blood sample for immunological analysis will be drawn at week 8 (visit v1). Informed consent form signed by the person(s) holding parental authority (both parents or mother only if the father has no parental authority) is needed for the infant to be included as well.

Diary cards will be used to follow the infant and the mother. If Infant and/or mother develop(s) suspected measles symptom(s), they will be evaluated by a study physician as soon as possible, preferably within 24 to 72 hours of acute measles symptom(s) onset.

In case of mother symptoms, infant will be also seen by a physician during mother's supplementary visit.

The visit at day 0 (V0) of the study will be performed at the maternity. The other visits, screening visit, V1 and supplementary visit (SV), will be performed either at the maternity or at the corresponding CIC if applicable. Home samples at 7, 11 and 14 days after vaccination will be directly sent at the laboratory of virology at Limoges. Home sampling can also be performed at the maternity or CIC according to their internal organization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: November 1, 2017
• Est. primary completion date: May 3, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 36 Years

Eligibility

Inclusion Criteria:

Women:

• Pregnant woman

• Age = 18 years

• Planning to breastfeed her infant (mixed feeding is allowed)

• Having a negative serology for rubella during pregnancy

• Negative serology for measles based on the result from local laboratory

• Affiliated to a social security regimen

Infants:

• Informed consent form signed by the person(s) holding parental authority.

• Term newborn (=36LMP)

Exclusion Criteria:

Women:

• Woman having a multiple pregnancy

• Woman planning to get pregnant in the month following the 2nd vaccination

• Woman with known or suspected HIV infection

• Woman with known or suspected immunodeficiency

• Woman with family history of hereditary immune deficiency

• Woman not mastering enough the reading / understanding of the French language to be able to consent to participate to the study

• Woman incapable to follow the procedures of the study and to respect study visits for the whole period of the study.

• Woman with contraindication for MMR vaccination:

• Scarce hereditary problems of fructose intolerance

• Woman with history of hypersensitivity to the active substances or to any of the excipients of the vaccine

• Administration of human gammaglobulins in the past 3 to 11 months depending on the dose of human globulins administered (except for Rhophylac®)

• Acute severe febrile illness within 7 days prior to injection

• Woman under systemic corticosteroids (prednisone, or equivalent =10 mg/day) within the previous 15 days or planning to use corticosteroids (i.e. prednisone, or equivalent =10 mg/day) during the 15 days following vaccination

• Woman under immunosuppressive therapy within the previous 3 months before vaccination or planning to use immunosuppressive therapy during the 15 days following vaccination Woman participating in any clinical trial with another investigational product 28 days prior to visit V0 or intent to participate in another clinical study with another investigational product at any time during the conduct of this study

• Any other reason which, according to the investigator, may interfere with the evaluation of the study objectives

• Woman with documented history of measles vaccination (1 or 2 doses) and/or history of documented measles

Infants:

• Blood draw is contraindicated or cannot be performed

• Infant with family history of hereditary immune deficiency

• Infant with suspected or confirmed immunodeficiency

• Any other reason which, according to the investigator, may interfere with the evaluation of the study objectives

Related Conditions & MeSH terms

• Measles
• Mumps
• Rubella

Intervention

Biological:
• Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®
One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.

Locations

Country	Name	City	State
France	Cochin Port Royal Hospital - Centre d'Investigation Clinique Cochin-Pasteur	Paris

Sponsors (4)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	GO-CIC network (Réseau Gynéco-Obstetrical des Centres d’Investigation Clinique), REIVAC network (Réseau National d’Investigation Clinique en Vaccinologie), Service de Bactériologie-Virologie-Hygiène, CHU Limoge

Country where clinical trial is conducted

France, 

References & Publications (4)

Alain S, Dommergues MA, Jacquard AC, Caulin E, Launay O. State of the art: Could nursing mothers be vaccinated with attenuated live virus vaccine? Vaccine. 2012 Jul 13;30(33):4921-6. doi: 10.1016/j.vaccine.2012.05.047. Epub 2012 May 31. Review. — View Citation

Chen LH, Zeind C, Mackell S, LaPointe T, Mutsch M, Wilson ME. Yellow fever virus transmission via breastfeeding: follow-up to the paper on breastfeeding travelers. J Travel Med. 2010 Jul-Aug;17(4):286-7. doi: 10.1111/j.1708-8305.2010.00430.x. — View Citation

Losonsky GA, Fishaut JM, Strussenberg J, Ogra PL. Effect of immunization against rubella on lactation products. I. Development and characterization of specific immunologic reactivity in breast milk. J Infect Dis. 1982 May;145(5):654-60. — View Citation

Losonsky GA, Fishaut JM, Strussenberg J, Ogra PL. Effect of immunization against rubella on lactation products. II. Maternal-neonatal interactions. J Infect Dis. 1982 May;145(5):661-6. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of the measles vaccine virus strain in breast milk.	Number of women with positive RT-PCR for measles vaccine virus strain in breast milk for at least one sample from day 7, 11 and 14 after postpartum vaccination with a combined measles-mumps-rubella (MMR) vaccine. RT PCR will be considered positive if the measurements exceed the limit of detection of 10 copies of genome per reaction	day 7 after the first vaccination.
Primary	Prevalence of the measles vaccine virus strain in breast milk.	Number of women with positive RT-PCR for measles vaccine virus strain in breast milk for at least one sample from day 7, 11 and 14 after postpartum vaccination with a combined measles-mumps-rubella (MMR) vaccine. RT PCR will be considered positive if the measurements exceed the limit of detection of 10 copies of genome per reaction	day 11 after the first vaccination.
Primary	Prevalence of the measles vaccine virus strain in breast milk.	Number of women with positive RT-PCR for measles vaccine virus strain in breast milk for at least one sample from day 7, 11 and 14 after postpartum vaccination with a combined measles-mumps-rubella (MMR) vaccine. RT PCR will be considered positive if the measurements exceed the limit of detection of 10 copies of genome per reaction	day 14 after the first vaccination.
Secondary	Number of infants with reported clinical symptoms of measles	Evaluation of the clinical impact of MMR vaccination in breastfeeding infant	At V1 Visit (8 weeks +/- 15 days)
Secondary	Number of infants with reported clinical symptoms of measles	Evaluation of the clinical impact of MMR vaccination in breastfeeding infant from data reported in the infant diary card (DiCa).	Between V0 visit and V1 visit (8 weeks +/- 15 days) after the first MMR vaccination
Secondary	Number of women with reported clinical symptoms of measles	Evaluation of the clinical impact of MMR vaccination in breastfeeding infant from mother clinical data	V1 Visit (8 weeks +/- 15 days) after the first MMR vaccination
Secondary	Number of women with reported clinical symptoms of measles	Evaluation of the clinical impact of MMR vaccination in breastfeeding infant from mother clinical data repoted in the diary card (DiCa).	Between V0 visit and V1 visit (8 weeks +/- 15 days) after the first MMR vaccination
Secondary	Number of infants with positive measles serology (IgM)	Evaluation of the immunological impact of MMR vaccination in breastfeeding infant.	V1 visit (8 weeks +/- 15 days) after the first MMR vaccination
Secondary	Number of women with positive RT-PCR for measles vaccine virus strain in urine in at least one sample	For detection of measles vaccine strain excretion in urine of breastfeeding women, the number of women, with negative rubella and measles serologies with positive RT-PCR for measles vaccine virus strain in urine for at least one sample from day 7, 11 and 14 after postpartum vaccination with a combined measles-mumps-rubella (MMR) vaccine will be assessed. RT PCR will be considered positive if the measurements exceed the limit of detection of 10 copies of genome per reaction	At day 7 after the first vaccination.
Secondary	Number of women with positive RT-PCR for measles vaccine virus strain in urine in at least one sample	For detection of measles vaccine strain excretion in urine of breastfeeding women, the number of women, with negative rubella and measles serologies with positive RT-PCR for measles vaccine virus strain in urine for at least one sample from day 7, 11 and 14 after postpartum vaccination with a combined measles-mumps-rubella (MMR) vaccine will be assessed. RT PCR will be considered positive if the measurements exceed the limit of detection of 10 copies of genome per reaction	At day 11 after the first vaccination.
Secondary	Number of women with positive RT-PCR for measles vaccine virus strain in urine in at least one sample	For detection of measles vaccine strain excretion in urine of breastfeeding women, the number of women, with negative rubella and measles serologies with positive RT-PCR for measles vaccine virus strain in urine for at least one sample from day 7, 11 and 14 after postpartum vaccination with a combined measles-mumps-rubella (MMR) vaccine will be assessed. RT PCR will be considered positive if the measurements exceed the limit of detection of 10 copies of genome per reaction	At day 14 after the first vaccination.
Secondary	Quantification of the measles vaccine virus strain presented in breast milk in at least one sample	In case of detection of measles vaccine virus strain excretion in breast milk, RT-PCR quantification measure of measles vaccine virus strain in woman breastmilk will be performed.	At day 7 after the first vaccination.
Secondary	Quantification of the measles vaccine virus strain presented in breast milk in at least one sample	In case of detection of measles vaccine virus strain excretion in breast milk, RT-PCR quantification measure of measles vaccine virus strain in woman breastmilk will be performed.	At day 11 after the first vaccination.
Secondary	Quantification of the measles vaccine virus strain presented in breast milk in at least one sample	In case of detection of measles vaccine virus strain excretion in breast milk, RT-PCR quantification measure of measles vaccine virus strain in woman breastmilk will be performed.	At day 14 after the first vaccination.
Secondary	Microscopy assessment of the infectious activity of the measles vaccine virus presented in breast milk in at least one sample.	In case of detection of measles vaccine virus strain excretion in breast milk. The evaluation of the infectious activity of the measles vaccine virus will be performed using an in vitro infectivity assay. A result will be considered as positive when at least one positive fluorescent cell is detected.	At day 7
Secondary	Microscopy assessment of the infectious activity of the measles vaccine virus presented in breast milk in at least one sample.	In case of detection of measles vaccine virus strain excretion in breast milk. The evaluation of the infectious activity of the measles vaccine virus will be performed using an in vitro infectivity assay. A result will be considered as positive when at least one positive fluorescent cell is detected.	At day 11 after the first vaccination.
Secondary	Microscopy assessment of the infectious activity of the measles vaccine virus presented in breast milk in at least one sample.	In case of detection of measles vaccine virus strain excretion in breast milk. The evaluation of the infectious activity of the measles vaccine virus will be performed using an in vitro infectivity assay. A result will be considered as positive when at least one positive fluorescent cell is detected.	At day 14 after the first vaccination.
Secondary	Number of infant with positive salivary IgM/IgG		one year after the first vaccination

External Links

•   Website of the CIC Cochin-Pasteur (CIC 1417) - 75679 Paris (France)